Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Investigation to Understand and Optimize Psilocybin

NCT: NCT06512194 · RECRUITING

NCT IDNCT06512194
StatusRECRUITING
Start Date2025-05-13
Completion2029-05
SponsorCharles Raison (OTHER)
First posted
Last updated

Brief Summary

This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.

Frequently Asked Questions

What is Investigation to Understand and Optimize Psilocybin?

Investigation to Understand and Optimize Psilocybin is a clinical trial registered under NCT06512194. Current status: RECRUITING.

What is the status of NCT06512194?

The current status of NCT06512194 (Investigation to Understand and Optimize Psilocybin) is: RECRUITING.

When did Investigation to Understand and Optimize Psilocybin start?

Investigation to Understand and Optimize Psilocybin started on 2025-05-13.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.